Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380649 | 0.83 | ESR2 (0.44) | KDM1AGRM5ESR2GPR119NR1H2 | |
| SCHEMBL6323174 | 0.83 | USP2 (0.36) | USP2SMN1; SMN2PIK3CAMTORCSNK2A1 | |
| SCHEMBL8334943 | 0.82 | USP2 (0.36) | USP2SMN1; SMN2PIK3CAMTORKDM1A | |
| SCHEMBL6327028 | 0.82 | L3MBTL1 (0.38) | USP2SMN1; SMN2PIK3CAMTORPIK3R1 | |
| SCHEMBL30474547 | 0.81 | MPO (0.41) | SMN1; SMN2KDM1AGRM5ESR2GPR119 | |
| SCHEMBL6190206 | 0.81 | MPO (0.41) | SMN1; SMN2KDM1AGRM5ESR2GPR119 | |
| SCHEMBL2492487 | 0.80 | FGFR4 (0.40) | USP2SMN1; SMN2KDM1ACSNK2A1CSNK2A2 | |
| SCHEMBL12654377 | 0.80 | MPO (0.41) | KDM1AGRM5ESR2GPR119NR1H2 | |
| SCHEMBL8334947 | 0.77 | ALDH1A1 (0.32) | USP2SMN1; SMN2PIK3CAMTORPIK3R1 | |
| SCHEMBL6260989 | 0.76 | CSNK2A1 (0.36) | USP2SMN1; SMN2KDM1ACSNK2A1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | USP2 4429/4885SMN1; SMN2 3478/4885PIK3CA 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.